KalVista Pharmaceuticals, Inc. Balance Sheet
KALV / Health Care|13 years of annual SEC 10-K data (FY2013-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 13 fiscal years. All figures from audited SEC 10-K filings.
KalVista Pharmaceuticals, Inc. had $251M in total assets and $95M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $131.6M | $31.8M | $56.2M | $30.7M | $50.6M | $15.8M | $32.0M | $2.5M | $30.9M | $21.8M | $2.5M | $481.0K | $9.8M |
| Current Assets | $241.7M | $225.7M | $172.3M | $193.6M | $264.3M | $88.7M | $115.5M | $59.4M | $34.2M | $24.7M | $54.9M | $4.6M | - |
| PP&E (Net) | $2.0M | $2.2M | $2.9M | $2.2M | $1.8M | $2.0M | $2.4M | $1.8M | $97.0K | $74.0K | $805.0K | $180.0K | - |
| Total Assets | $250.8M | $235.4M | $183.2M | $203.9M | $272.0M | $92.5M | $118.1M | $61.4M | $34.3M | $24.7M | $56.8M | $6.6M | - |
| Current Liabilities | $45.2M | $22.8M | $15.0M | $11.6M | $9.8M | $7.7M | $18.1M | $23.2M | $3.0M | $3.2M | $4.3M | $7.1M | - |
| Shareholders' Equity | $95.4M | $206.6M | $161.0M | $185.1M | $257.2M | $83.8M | $96.7M | -$23.6M | $31.3M | -$37.1M | -$23.6M | -$16.2M | -$33.7M |